Cincinnati pharma firm inks deal that could be worth over $400M

Aerpio Pharmaceuticals Inc. revealed today that that company has signed a licensing agreement that could be worth more than $400 million.

The Blue Ash-based firm (OTCQB: ARPO) will be paid $20 million up front by GB004 Inc. for an Aerpio stabilizer in development to treat inflammatory bowel disease.

Click here to read the complete article. Story excerpt provided by Cincinnati Business Courier. Written by Barrett J. Brunsman. Originally published June 25, 2018.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: